Luqa Pharmaceuticals, a Hong Kong company that specializes in dermatology products, has in-licensed exclusive China rights to Strataderm®, a scar treatment, from Stratpharma AG of Switzerland. Strataderm has already been approved by the SFDA; Luqa plans to begin marketing the drug to hospital and retail accounts in Q4 of 2012. More details.... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});